A new study of an estrogen-derived drug shows promise as a treatment for breast cancer and breast cancer metastases to bone. A drug that has shown promise in treating sarcoma, lung and brain cancers, demonstrates that the drug may also be effective in treating breast cancer, in particular the spread of breast cancer.
Une nouvelle étude d'un médicament d'un dérivé de l'ostrogène montre des promesses comme traitement pour le cancer du sein et pour le cancer du sein métatstasé dans les os. Un médicament qui a montré ausi des promesses pour traiter les sarcomes, le cancer du et le cancer du pourrait aussi être efficace pour le traitement du cancer du en particulier celui qui s'est métastasé aux os. The study, which was done in mice, appears on the cover of the November issue of Cancer Research.
L'étude qui a été faite chez les souris apparait sur le numéro de Novembre de
Cancer ResearchIwaniec and Turner studied the effect of 2-methoxyestradiol (meth-oxy-es-tra-di-ol), or 2ME2, on the bone. 2ME2 is derived from estrogen and works by suppressing tumor growth and blocking the formation of new blood vessels that feed tumors.
Les chercheurs ont étudié l'effet de 2-methoxyestradiol, ou 2ME2, sur les os. 2ME2 est dérivé de l'ostrogène et travaille en supprimant la croissance de la tumeur et en bloquant la formation de nouveaux vaisseaux qui alimentetn les tumeurs."We were expecting the drug to have an effect, but we were not expecting to have as big of an effect as it did," Iwaniec said.
"nous nous attendions à ce que le médicament ait un effet mais pas un si gros effet qu'il a eu." a dit Iwaniec. In studies of other cancers, 2ME2 has been shown to induce cancer cells to self-destruct. Otherwise, tumor cells evade this process allowing them to continually divide and spread throughout the body.
Clinical trials of 2ME2 for breast cancer patients are in progress. These trials are based on an oral version of 2ME2 to treat primary tumors, but this method has limitations as the oral version of 2ME2 is poorly suited to getting into the blood system and reaching tumors. Researchers resolved this problem by delivering 2ME2 by injection and found it was much more effective.
Des essai de 2ME2 pour le cancer du sont en cours. Ces essais sont basés sur une version du médicament prise oralement pour traiter les tumeurs primaires, mais cette méthode ne convient pas tout à fait parce que cette version du médicament a de la difficulté à atteindre les tumeurs. Les chercheurs ont résolu cela en injectant le médicament directement dans la tumeur.Researchers described 2ME2 as an "attractive candidate for controlling tumor growth, metastasis to bone and bone disorders," such as osteolysis caused by the spread of breast cancer.
"This is potentially of very substantial importance because this agent has few of the unpleasant side effects of most chemotherapy drugs and targets both bone resorption and the cancerous tumor cells," Turner said. "It really is the first agent that has been clearly demonstrated to do that."
Les chercheurs ont décrit le médicament comme un candidat séduisant pour controler la croissance de la tumeur et les métastases dans les os comme l'osteolysis causé par le cancer du C'est un agent qui a peu d'effet secondaire et peude médicament cible à la fois la tumeur et la métastase dans les os.Turner said current drugs that are used to prevent bone fractures and bone pain in cancer patients are not effective in targeting the tumor cells. Turner has spent the past decade studying 2ME2 as a treatment for osteoporosis and a rare bone cancer called osteosarcoma, and is excited about its prospects as a cancer treatment.
"Often, treatments that are good for cancer are bad for the bones," he said. "2ME2 appears to be capable of treating both. If you had a treatment that both reduced the risk of bone cancer and osteoporosis, it would be extremely significant."
In summary, the researchers found that 2ME2 could:
Effectively target breast cancer cells;
Prevent the spread of breast cancer cells to bone;
Protect bone from osteolysis, which is a type of bone metastasis in which the bone is eaten away by cancer cells.
The next step for the Mayo Clinic and OSU researchers is to replicate and test the finding in clinical trials.
The study was funded by a grant from the National Institutes of Health and the Mayo Clinic.
The study's authors include: Muzaffer Cicek, Merry Jo Oursler, Anne Vrabel and Ming Ruan of the Mayo Clinic; and Michael Goblirsch and Denis Clohisy of the University of Minneapolis Cancer Center.